Metastatic NSCLC
Showing 1 - 25 of >10,000
NSCLC Trial (Sutetinib Maleate Capsule)
Not yet recruiting
- Non-small Cell Lung Cancer
- Sutetinib Maleate Capsule
- (no location specified)
Aug 18, 2023
Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - NSCLC Trial in Kansas City, Overland Park, Lee's Summit (Cabozantinib,
Not yet recruiting
- Lung Cancer
- +3 more
-
Kansas City, Kansas
- +3 more
May 12, 2023
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48 Trial in Guanzhou (RC48+Tislelizumab+carboplatin,
Not yet recruiting
- Non Small Cell Lung Cancer
- +3 more
- RC48+Tislelizumab+carboplatin
- +2 more
-
Guanzhou, ChinaSunYat-senU
May 5, 2023
A Multicountry, Multicentre, Non-interventional, Retrospective
Recruiting
- Carcinoma, Non-Small-Cell Lung
-
Kuwait, KuwaitKuwait Cancer Control Center
Sep 13, 2023
Metastatic NSCLC MET Exon 14 Skipping Mutation and Brain
Completed
- Metastatic Non-Small Cell Lung Cancer
-
East Hanover, New Jersey18 Novartis Investigative Sites in the US
Dec 29, 2022
Locally Advanced or Metastatic NSCLC Trial in Ohio City (PBF-1129)
Active, not recruiting
- Locally Advanced or Metastatic NSCLC
-
Ohio City, OhioDivision of medical Oncology A450B Starling Loving Hall
Jan 24, 2023
KRAS P.G12C, Non Small Cell Lung Cancer Trial in France (Sotorasib 120Mg Tab)
Recruiting
- KRAS P.G12C
- Non Small Cell Lung Cancer
- Sotorasib 120Mg Tab
-
Lyon, France
- +3 more
Dec 16, 2022
Lazertinib as the 2nd-Line Treatment in EGFR Mutation+ NSCLC
Completed
- Non-small Cell Lung Cancer
- Lazertinib
- Platinum-based Chemotherapy
- (no location specified)
May 8, 2023
Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples
Recruiting
- Non-squamous Lung Cancer
- Metastatic Lung Cancer
- Blood
- +3 more
-
Tours, FranceUniversity hospital
Nov 7, 2022
Metastatic Non Small Cell Lung Cancer, KRAS G12C Trial in Worldwide (Sotorasib, Lenvatinib)
Not yet recruiting
- Metastatic Non Small Cell Lung Cancer
- KRAS G12C
-
Innsbruck, Austria
- +14 more
Sep 28, 2023
Non-Small-Cell Lung Cancer Trial in Shanghai (Furmonertinib (160mg))
Recruiting
- Non-Small-Cell Lung Cancer
- Furmonertinib (160mg)
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 2, 2022
NSCLC Trial (KB-GDT-01)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- KB-GDT-01
- (no location specified)
Sep 29, 2023
NSCLC (NSCLC) Trial (Ociperlimab, Placebo, Tislelizumab)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Ociperlimab
- +8 more
- (no location specified)
Mar 17, 2023
NSCLC (NSCLC) Trial in New York (Pembrolizumab)
Not yet recruiting
- Non-Small Cell Lung Cancer (NSCLC)
-
New York, New YorkMount Sinai Hospital
Jan 23, 2023
NSCLC, Melanoma Trial (IMM60, Pembrolizumab)
Not yet recruiting
- Non-small Cell Lung Cancer
- Melanoma
- (no location specified)
Jan 24, 2023
Non Small Cell Lung Cancer Trial in Shanghai (HS-10241)
Recruiting
- Non Small Cell Lung Cancer
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Jun 19, 2022
NSCLC Trial in Heidelberg (89Zirconium-M7824, M7824)
Terminated
- Non-Small Cell Lung Cancer
- 89Zirconium-M7824
- M7824
-
Heidelberg, Victoria, AustraliaAustin Health
Jan 13, 2023
NSCLC Trial in Changsha, Shanghai, Hangzhou (H002 capsule)
Recruiting
- Non-small Cell Lung Cancer
- H002 capsule
-
Changsha, Hunan, China
- +2 more
Sep 20, 2022
Advanced or Metastatic NSCLC Trial in Guangzhou (HS-10375)
Recruiting
- Advanced or Metastatic NSCLC
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jun 27, 2022
Metastatic Non-Small Cell Lung Carcinoma Trial in Seoul (Pembrolizumab Injection)
Recruiting
- Metastatic Non-Small Cell Lung Carcinoma
- Pembrolizumab Injection
-
Seoul, Korea, Republic ofSamsung Medical Center
Nov 6, 2022
Locally Advanced or Metastatic NSCLC Patients, Progressed From
Active, not recruiting
- Locally Advanced or Metastatic NSCLC
-
Beijing, China
- +16 more
Dec 16, 2022